Dec 22, 2022 | Diane Hunter
My attendance at the 64th Annual Society of Hematology Annual Meeting, in New Orleans, LA, 12/9-12/2022 was an amazing experience. As a first-time attendee, I was at times overwhelmed because the target audience for the information presented was medical professionals,...
Dec 22, 2022 | Diane Hunter
My first visit to the 64th American Society of Hematology Annual Meeting Exhibit Hall was impressive. A conversation with Darrin Gansebom at the Takeda Oncology booth was a highlight. Teresa Miceli and I introduced ourselves and expressed our gratitude for Takeda...
Dec 22, 2022 | Diane Hunter
I am a five-year multiple myeloma (MM) survivor, taking Revlimid and having quarterly Zometa infusions for bone strengthening. I have been thinking about having a conversation with my oncologist about is it necessary for me to continue my maintenance treatment. At the...
Dec 22, 2022 | Gail McCray
Overall: As with every ASH, we are able to witness up close and personal the exciting advances in science and medicine – the research moving us more and more towards precision medicine, the current clinical trials (phases I, II, and III) and the medications approved...
Dec 22, 2022 | Gail McCray
Excitement and a bit of trepidation are the emotions I would attribute to the eve of my third opportunity to attend the 64th American Society of Hematology Annual Meeting. I will attend virtually this year, as I did last year. There are quite a few of our Support...
Dec 22, 2022 | Teresa Miceli
Attending the 64th American Society of Hematology (ASH) Annual Meeting, I am continually reminded of how far we have come in the treatment landscape of multiple myeloma (MM) since I became a nurse I 1991. Acronyms of drug regimens that, for the most part, are no...
